HORIZON is the phase 3 clinical trial program of Wyeth's investigational drug temsirolimus oral tablets in combination with letrozole (Femaraâ) (a currently approved breast cancer therapy) for first-line use in postmenopausal women with hormone-receptor positive metastatic breast cancer.
Wyeth Pharmaceuticals (a Wyeth Division) yesterday announced its decision to discontinue the HORIZON study, based upon the recommendation of an Independent Data Monitoring Committee (IDMC) after review of data from a planned interim analysis. The IDMC advised that continuation of the trial was unlikely to achieve the targeted level of efficacy for the combination therapy compared to letrozole alone. IDMC came to the conclusion that the risk/benefit ratio for treatment of metastatic breast cancer did not favor continuation and recommended that the trial be discontinued.
However, Wyeth Pharmaceuticals remain committed in studying temsirolimus in other cancer indications. In fact, there are 2 other phase 3 clinical trials of the intravenous formulation of temsirolimus in renal cell carcinoma and mantle cell lymphoma.
Source: Wyeth Press Release
.jpg)
Comment Preview